

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

**北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

### **SUPPLEMENTAL ANNOUNCEMENT**

#### **CONTINUING CONNECTED TRANSACTIONS:**

- (1) 2026 STAIDSON RESEARCH AND DEVELOPMENT SERVICE  
FRAMEWORK AGREEMENT; AND  
(2) 2026 BIOAI SERVICE FRAMEWORK AGREEMENT**

Reference is made to the announcement of the Company dated 5 December 2025 (the “**CCT Announcement**”) regarding the 2026 Staidson Research and Development Service Framework Agreement and the 2026 BioAI Service Framework Agreement. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the CCT Announcement.

As disclosed in the CCT Announcement, the Company has taken into account factors in determining the proposed annual caps of the continuing connected transactions contemplated under the 2026 Agreements. The Company would like to provide further information in relation to the basis of the proposed annual caps.

#### **CONTINUING CONNECTED TRANSACTIONS**

##### **2026 Staidson Research and Development Service Framework Agreement**

##### **Proposed Annual Cap and Basis for Annual Cap under the 2026 Staidson Research and Development Service Framework Agreement**

In arriving at the proposed annual cap of RMB47 million, the Company has taken into account the following factors: (i) the fact that Staidson intends to engage the Company in a large number of projects for the year ending 31 December 2026 and the expected demand of Staidson for the drug research and development services for the year ending 31 December 2026; (ii) the historical transaction amounts with Staidson; (iii) the labour and equipment costs of the drug research and development services; and (iv) the capacity of the Company to provide the drug research and development services.

For factor (ii) above, the historical transaction amount during the period from 1 January 2025 to 30 November 2025 was approximately RMB15.04 million. The estimated total transaction amount for 2025, at the time of determining the annual cap under the 2026 Staidson Research and Development Service Framework Agreement, was expected to be lower than the expected cap amount under the 2025 Staidson Research and Development Service Framework Agreement mainly due to the slow-down of project implementation of certain research and development projects in response to the change in market environment and Staidson's adjustments in research and development.

For factors (i), (ii), (iii) and (iv) above, the Company anticipates that there will be non-clinical and clinical services projects in 2026. The non-clinical and clinical projects to be commenced in 2026 have completed preliminary project initiation. The subsequent progress of the projects would be subject to the actual market environment and Staidson's adjustments in research and development.

After taking into account the labour and equipment costs and Company's capacity of the drug research and development services, as well as the project progress forecast of various projects, the Company estimates that the anticipated payment to be received from non-clinical and clinical services projects in 2026, together with the corresponding payments to be collected in 2026 for certain projects from previous years, based on their research and development progress, will approximately be RMB47 million.

Therefore, the proposed annual cap is set at RMB47 million. The relevant highest applicable percentage ratio exceeds 0.1% but less than 5%. Therefore, the continuing connected transactions contemplated under the 2026 Staidson Research and Development Service Framework Agreement shall be subject to the reporting, announcement and annual review requirements but exempt from circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

## **2026 BioAI Service Framework Agreement**

### **Proposed Annual Cap and Basis for Annual Cap under the 2026 BioAI Service Framework Agreement**

In arriving at the proposed annual cap of RMB16.5 million, the Company has taken into account the following factors: (i) the expected demand of the Company for the projects of software development, automation development, system integration services, and technical services related to digital and intelligent production and operation; and (ii) the expected cost for providing the above services by BioAI.

The historical unaudited transaction amount during the period from 1 January 2025 to 31 December 2025 was RMB10.3 million.

For factors (i) and (ii) above, the Company anticipated the transaction amount in 2026 is based on (1) the ongoing continuing connected transactions in 2025 between the Company and BioAI to be continued in 2026; (2) the number of projects in 2026 being 1 to 2 more than that in 2025; and (3) the expected cost for providing the services by BioAI includes labour expenses for services such as laboratory-related system software development and data management system optimisation, together with operational management fees arising from software development services provided at various project stages. These costs are determined based on the project requirements in 2026 and would be subject to fluctuation.

Therefore, the proposed annual cap is set at RMB16.5 million. The relevant highest applicable percentage ratio exceeds 0.1% but less than 5%. Therefore, the continuing connected transactions contemplated under the 2026 BioAI Service Framework Agreement shall be subject to the reporting, announcement and annual review requirements but exempt from circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

### **OPINIONS OF THE BOARD**

In determining the annual caps of the 2026 Agreements, the Board (including the independent non-executive Directors) has considered and balanced the factors as elaborated above and is of the view that the annual caps of the 2026 Agreements are determined on normal commercial terms, fair and reasonable, and are in the interest of the Company and shareholders as a whole.

Shareholders should note that the annual caps of the 2026 Agreements represent the best estimates by the Directors of the amounts of the relevant transactions based on the information currently available. The annual caps of the 2026 Agreements bear no direct link, nor constitute a guide or commitment to the Group's future financial information or performance.

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC  
12 January 2026

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Ms. Sun Yunxia, Mr. Gao Dapeng, Mr. Gu Jingliang and Ms. Luo Xi as executive Directors, Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan and Mr. Ying Fangtian as independent non-executive Directors, and Ms. Li Ye as employee Director.*